All Pharma News
Nurix Announces Closing of Public Offering, Underwriters` Option Exercise

Nurix Announces Closing of Public Offering, Underwriters` Option Exercise
GLOBENEWSWIRE
16 Apr 2024
Share Share
Nurix Therapeutics Announces Proposed Public Offering

Nurix Therapeutics Announces Proposed Public Offering
GLOBENEWSWIRE
11 Apr 2024
Share Share
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
GLOBENEWSWIRE
11 Apr 2024
Share Share
Nurix Therapeutics Reports Q1 2024 Financials, Corporate Update

Nurix Therapeutics Reports Q1 2024 Financials, Corporate Update
GLOBENEWSWIRE
10 Apr 2024
Share Share
Nurix Extends Collaboration with Sanofi for STAT6 Protein Degraders

Nurix Extends Collaboration with Sanofi for STAT6 Protein Degraders
GLOBENEWSWIRE
09 Apr 2024
Share Share
Nurix Reports CNS Activity of NX-5948, BTK Degrader in Develop for Malignancies

Nurix Reports CNS Activity of NX-5948, BTK Degrader in Develop for Malignancies
GLOBENEWSWIRE
09 Apr 2024
Share Share
Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics to Participate in Upcoming Investor Conferences
GLOBENEWSWIRE
03 Apr 2024
Share Share
Gilead dives deeper into Nurix protein degrader collab

Gilead dives deeper into Nurix protein degrader collab
James Waldron FIERCE BIOTECH
02 Apr 2024
Share Share
Nurix Therapeutics is Part of a Team of International Oncology Experts

Nurix Therapeutics is Part of a Team of International Oncology Experts
GLOBENEWSWIRE
25 Mar 2024
Share Share
Nurix Presents the Discovery First-in-Class CBL-B Inhibitor NX-1607

Nurix Presents the Discovery First-in-Class CBL-B Inhibitor NX-1607
GLOBENEWSWIRE
20 Mar 2024
Share Share